Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.
about
Incomplete CD8(+) T lymphocyte differentiation as a mechanism for subdominant cytotoxic T lymphocyte responses to a viral antigenInduction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer.Genomic expression analysis by single-cell mRNA differential display of quiescent CD8 T cells from tumour-infiltrating lymphocytes obtained from in vivo liver tumours.T-cell recognition of melanoma-associated antigens.MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies.T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.Flanking residues are central to DO11.10 T cell hybridoma stimulation by ovalbumin 323-339.Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses.Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes.An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes.Mobilizing the low-avidity T cell repertoire to kill tumors.In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.Induced transgene expression for the treatment of solid tumors by hematopoietic stem cell-based gene therapy.Visualizing CTL/melanoma cell interactions: multiple hits must be delivered for tumour cell annihilation.Effector cytolotic function but not IFN-gamma production in cytotoxic T cells triggered by virus-infected target cells in vitro.Creating HIV-1 reverse transcriptase cytotoxic T lymphocyte target structures by HLA-A2 heavy chain modifications.Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.High frequency of T cells specific for cryptic epitopes in melanoma patientsLipid Inflammatory Mediators in Cancer Progression and Therapy.Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen
P2860
Q30305658-6E0C110F-8D08-4D82-AA2A-1D8128BE2102Q33340683-81F1EACE-FD24-44CB-80F4-7F445A8E9783Q33367752-5104B48C-021D-4FD3-8802-BD6AD5AA1929Q33827458-0E119DEA-2399-4AEB-9A30-7F9CF529ADA4Q34196069-74EB385E-BD18-44E4-9601-C556553C08DFQ34452013-ABCCCAFB-E48D-42C2-AFA1-AC91541599D4Q34460478-292B21A7-E622-4F73-A499-EA5F143489C5Q34791108-79E333BE-A54A-4FA2-B352-2E00501A51E9Q35851748-4160F75D-4065-4212-BAB8-37AAF92411A8Q36610161-66FB91C9-25E0-4EC5-A089-B3FB854C4FBCQ36638199-29AC4B5C-A72D-4DC7-835D-7085714DB19BQ36673743-90E9F7D8-AEB0-4B9F-BB6B-43C1380B2A46Q36891310-F6A7BCDB-EF57-44A9-B6F7-E0D522C210D9Q36959354-F13F8C36-97AE-4F57-8D32-65E42F1C01BCQ37486804-DDFA5D81-91E2-43B6-91F6-475B70C78D56Q39382972-4B351CE8-7A79-4B64-A9A3-AB73099598F9Q39862902-89A1EB55-5EF2-4E44-91B1-474B9E8952F3Q40780809-7D0F51AE-F842-43AC-8D56-18E8217A15DFQ40857790-88D66EFB-ACB3-46AC-AF71-56A6A18826E7Q40913310-F0600428-1A18-4A09-9CB0-E6E9231D41CAQ42141424-1CC6167D-A579-445C-863F-C3662E6F389EQ49592855-2859C866-EE4C-4454-82B7-F859C4F92E5BQ52013647-6098C235-592A-42D4-BF13-EDE027B1131CQ54628562-F211C8FE-7800-4CCC-AE79-578C0E847131Q57209300-F53622CF-03F4-48AF-B44D-0CF1D2B9B882
P2860
Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Suboptimal activation of melan ...... HC-tumor peptide interactions.
@ast
Suboptimal activation of melan ...... HC-tumor peptide interactions.
@en
type
label
Suboptimal activation of melan ...... HC-tumor peptide interactions.
@ast
Suboptimal activation of melan ...... HC-tumor peptide interactions.
@en
prefLabel
Suboptimal activation of melan ...... HC-tumor peptide interactions.
@ast
Suboptimal activation of melan ...... HC-tumor peptide interactions.
@en
P2093
P2860
P356
P1476
Suboptimal activation of melan ...... HC-tumor peptide interactions.
@en
P2093
P2860
P304
P356
10.1084/JEM.183.5.2403
P407
P577
1996-05-01T00:00:00Z